Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9(*)3 allele

Pharmacogenetics

Volumn 9, Issue 1, 1999, Pages 71-80

  Kidd, Robert S ^a   Straughn, Arthur B ^b   Meyer, Marvin C ^b   Blaisdell, Joyce ^c   Goldstein, Joyce A ^c   Dalton, James T ^b  

^a SHENANDOAH UNIVERSITY   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Cytochrome P450; Pharmacokinetics; Phenytoin; Polymorphism

Indexed keywords

CHLORPHENIRAMINE; CYTOCHROME P450; CYTOCHROME P450 3A4; DEBRISOQUINE 4 HYDROXYLASE; GLIPIZIDE; NIFEDIPINE; PHENYTOIN; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CASE REPORT; CAUCASIAN; DRUG BIOAVAILABILITY; DRUG CLEARANCE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0032891790     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199902000-00010     Document Type: Article

References (32)

1. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P-450 oxidoreductase. Pharmacogenetics 1997; 7:203-210.
2. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6:193-201.
3. Ferguson RJ, de Morais SMF, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, et al. A novel defect in human CYP2C19: mutation of the initation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998; 284:356-361.
4. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, Idle JR. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995; 5:389-392.
5. Goldstein JA, Blaisdell J. Genetic tests which identify the principle defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. In: Johuson EF, Waterman MR, editors. Methods in enzymology. Vol. 272, Cytochrome P450, Part B. San Diego, CA: Academic Press; 1996, pp. 210-217.
6. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4:285-299.
7. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Raucy JI, Kitareewan S, et al. Evidence for a role for 2C19 in metabolism of S-mephenytoin in humans. Biochemistry 1994; 33:1743-1752.
8. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 1992; 267:83-90.
9. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereospecificity, and prochiral selectivity of the wild-type and 1359L mutant forms. Arch Biochem Biophys 1996; 333:447-458.
10. Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer P, et al. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 1998; 286: 1490-1495.
11. Inaba T. Phenytoin: pharmacogenetic polymorphism of 4-hydroxylation. Pharmacol Ther 1990; 46:341-347.
12. Kaminsky LS, de Morais SM, Faletto MB, Dunbar D, Goldstein JA. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol 1993; 43:234-239.
13. Kenny SJ, Aubert RE, Geiss LS. Prevalence and incidence of non-insulin-dependent diabetes. In: NIH Publication no. 95-1468, Diabetes in America, 2nd edn. Bethesda, MD; 1995.
14. London SJ, Sullivan-Klose T, Daly AK, Idle JR. Lung cancer risk in relation to the CYP2C9 genetic polymorphism in Caucasians in Los Angeles County. Pharmacogenetics 1997; 7:401-404.
15. Miners JO, Wing LMH, Birkett DJ, Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metabolizer. Aust NZ J Med 1985; 15:348-349.
16. Odani A, Hashimoto Y, Otsuki Y, Uwai Y, Hattori H, Furusho K, Inui K. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 1997; 62:287-292.
17. Page MA, Boutagy JS, Shenfield GM. A screening test for slow metabolisers of tolbutamide. Br J Clin Pharmacol 1991; 31:649-654.
18. Rettie A, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4:39-42.
19. Richardson TH, Griffin KJ, Jung F, Raucy JL, Johnson EF. Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys 1997; 338:157-164.
20. Rieutord A, Stupans I, Shenfield GM, Gross AS. Gliclazide hydroxylation by rat liver microsornes. Xenobiotica 1995; 25:1345-1354.
21. Romkes M, Faletto MR, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450HC subfamily. Biochemistry 1991; 30:3247-3255.
22. Rosner B. Descriptive statistics. In Fundamentals of biostatistics. 4th edn. Duxbury Press, Belmont, CA; 1995.
23. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividnal variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 50 Caucasians. J Pharmacol Exp Ther 1994; 270:414-423.
24. Spielberg S, McCrea J. Cribb A, Rushmore T, Waldman S, Bjornsson T, et al. A mutation in CYP2C9 is responsible for decreased metabolism of losartan. Clin Pharmacol Ther 1996; 59:215.
25. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, Rettie AE. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997; 7:361-367.
26. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, et al. The role of the CYP2C9-Leu 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6:341-349.
27. Szorady I, Santa A. Pharmacogenetically hazardous drugs: a proposed new scoring method. Acta Physiol Hung 1991; 77:305-318.
28. Tassaneeyakul W, Birkett DJ, Pass MC, Miner JO. Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo. Br J Clin Pharmacol 1996; 42:774-778.
29. Vermeij P, Perrari MD, Buruma OJ, Veenema H, de Wolff FA. Inheritance of poor phenytoin parahydroxylation capacity in a Dutch family. Clin Pharmacol Ther 1988; 44:588-593.
30. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DLP, et al. Site directed mutation studies of human liver cytochrome P-450 isozymes in the CYP2C subfamily. Biochem J 1993; 289:533-538.
31. Wang SL, Huang J, Lai MD, Tsai JJ. Detection of the CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995; 5:37-42.
32. Xiao ZS, Goldstein JA, Xie H-G, Blaisdell J, Wang W, Jiang C-H, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997; 281:604-609.